Pulmonary Fibrosis - Pipeline Review, H1 2012

Global Markets Direct, May 2012, Pages: 58

Pulmonary Fibrosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Pulmonary Fibrosis - Pipeline Review, H1 2012', provides an overview of the Pulmonary Fibrosis therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. 'Pulmonary Fibrosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pulmonary Fibrosis.
- A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Pulmonary Fibrosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Pulmonary Fibrosis Therapeutic Products under Development, Key Players in Pulmonary Fibrosis Therapeutics, Pulmonary Fibrosis Pipeline Overview, Pulmonary Fibrosis Pipeline, Pulmonary Fibrosis Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Fibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Pulmonary Fibrosis
Pulmonary Fibrosis Therapeutics under Development by Companies
Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Pulmonary Fibrosis Therapeutics – Products under Development by Companies
Pulmonary Fibrosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Pulmonary Fibrosis Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Lpath, Inc.
Pharmaxis Ltd.
Paloma Pharmaceuticals, Inc.
Digna Biotech, S.L.
Advinus Therapeutics Pvt. Ltd.
Aquinox Pharmaceuticals Inc.
Five Prime Therapeutics, Inc.
Pulmonary Fibrosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GC1008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZX100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXS25 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Losartan + Zileuton + N-Acetylcysteine + Prevastatin + Erythromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Deskar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Palomid 529 Inhalant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Btx201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM095 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PNQ-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmonary Fibrosis Therapeutics – Drug Profile Updates
Pulmonary Fibrosis Therapeutics – Discontinued Products
Pulmonary Fibrosis Therapeutics - Dormant Products
Pulmonary Fibrosis – Product Development Milestones
Featured News & Press Releases
May 08, 2012: Boehringer Ingelheim To Present Additional Data From Phase II Study Of BIBF 1120 At ATS 2012
Jul 06, 2011: Capstone Reports Positive Pre-Clinical Results Of AZX100 In Pulmonary Fibrosis
May 18, 2009: Oncothyreon's PX-866 Is Effective In Preclinical Model Of Pulmonary Fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Pulmonary Fibrosis, H1 2012
Products under Development for Pulmonary Fibrosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Lpath, Inc., H1 2012
Pharmaxis Ltd., H1 2012
Paloma Pharmaceuticals, Inc., H1 2012
Digna Biotech, S.L., H1 2012
Advinus Therapeutics Pvt. Ltd., H1 2012
Aquinox Pharmaceuticals Inc., H1 2012
Five Prime Therapeutics, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Pulmonary Fibrosis Therapeutics – Drug Profile Updates
Pulmonary Fibrosis Therapeutics – Discontinued Products
Pulmonary Fibrosis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Pulmonary Fibrosis, H1 2012
Products under Development for Pulmonary Fibrosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Kidney Fibrosis - Pipeline Review, H1 2013
• Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2013
• Liver Fibrosis - Pipeline Review, H1 2013
• Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2012
• Cystic Fibrosis - Pipeline Review, H1 2013
• Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2012
• Liver Fibrosis - Pipeline Review, H1 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Kidney Fibrosis - Pipeline Review, H2 2012
• Global Pulmonary Fibrosis Pipeline Capsule - 2013